Dose (mg/ day) | No. of patients | Change (%),median (range) | p Value | ||
vs 150 mg | vs 600 mg | ||||
Gender | |||||
Male | 150 | 97 | −14.9 (−80.7 to +375.9) | ||
600 | 117 | −33.1 (−88.3 to +93.1) | <0.001 | ||
900 | 123 | −36.4 (−79.1 to +1696.9) | <0.001 | 0.430 | |
Female | 150 | 98 | −18.0 (−79.0 to +175) | ||
600 | 81 | −25.0 (−74.7 to +95.2) | 0.058 | ||
900 | 70 | −35.8 (−81.4 to +315.3) | 0.002 | 0.076 | |
Body weight (kg) | |||||
<60 | 150 | 115 | −14.9 (−80.7 to +375.9) | ||
600 | 82 | −28.6 (−74.7 to +95.2) | 0.002 | ||
900 | 91 | −35.2 (−81.4 to +315.3) | 0.001 | 0.356 | |
⩾60 | 150 | 80 | −16.7 (−73.4 to +166.1) | ||
600 | 116 | −30.3 (−88.3 to +93.1) | 0.003 | ||
900 | 102 | −36.6 (−77.1 to +1696.9) | <0.001 | 0.096 | |
GGT (IU/l) | |||||
⩽39 | 150 | 45 | −14.5 (−73.4 to +71.4) | ||
600 | 39 | −32.7 (−62.9 to +93.1) | 0.049 | ||
900 | 45 | −26.6 (−81.4 to +1696.9) | 0.112 | 0.616 | |
40–79 | 150 | 79 | −15.2 (−69.1 to +175) | ||
600 | 90 | −30.3 (−74.7 to +95.2) | 0.001 | ||
900 | 70 | −36.3 (−77.7 to +200) | <0.001 | 0.633 | |
⩾80 | 150 | 71 | −18.2 (−80.7 to +375.9) | ||
600 | 69 | −28.6 (−88.3 to +53.8) | 0.057 | ||
900 | 78 | −41.2 (−79.1 to +119.3) | <0.001 | 0.004 |
The p values refer to Wilcoxon signed-ranks tests.